Sunshine Reporting Sample Clauses

Sunshine Reporting. Olema will be responsible for reporting payments and other transfers of value made to health care professionals (e.g. investigators, steering committee members, data monitoring committee members, consultants, etc.) in connection with the Study in accordance with reporting requirements, if any, under Applicable Law (including the Physician Payment Sunshine Act and analogous state gift laws applicable to the activities hereunder, and the European Federation of Pharmaceutical Industries and Associations Disclosure Code of Transfers of Value) and Olema policies (unless inconsistent with Applicable Law). Novartis shall provide all information required for such reporting regarding the value of the Novartis Compound provided for use in the Study. Such information shall be provided to the point of contact within ▇▇▇▇▇’s clinical supplies group who is identified to Novartis in writing upon the execution of the Agreement and thereafter promptly following any change to such point of contact. Novartis shall provide the necessary information regarding the value of the Novartis Compound within [***] after the Effective Date. If at any time during the term of this Agreement, the value of the Novartis Compound provided to Olema changes, Novartis shall notify Olema of such revised value, and the effective date of such revised value, within [***] after such change in value.

Sunshine Reporting. Sponsor will be responsible for reporting payments and other transfers of value made to health care professionals (e.g. investigators, steering committee members, data monitoring committee members, consultants, etc.) in connection with its role as Sponsor of the Study in accordance with reporting requirements, if any, under Applicable Law (including the Physician Payment Sunshine Act and state gift laws, and the European Federation of Pharmaceutical Industries and Associations Disclosure Code) and Sponsor policies. Lilly shall provide all information required for such reporting regarding the value of the Lilly Compound provided for use in the Study. Such information shall be provided to the point of contact within Sponsor's clinical supplies group who is identified to Lilly in writing upon the execution of the Agreement and thereafter promptly following any change to such point of contact. Lilly shall provide the necessary information regarding the value of the Lilly Compound within [***] business days following the execution of this Agreement. In the event that, at any time during the term of this Agreement, the value of the Lilly Compound provided under this Agreement changes, Lilly shall notify Sponsor of such revised value, and the effective date of such revised value, within [***] business days following such change in value. ARTICLE

Sunshine Reporting. Sponsor has the responsibility, as the sponsor of the Study, for reporting payments and other transfers of value made to health care professionals (e.g. investigators, steering committee members, data monitoring committee members, consultants, etc.) in connection with the Study in accordance with reporting requirements, if any, under Sunshine Laws and Sponsor policies. ▇▇▇▇▇ shall provide all information and support reasonably required for such reporting regarding the value of the Lilly Compound provided for use in the Study. Such information shall be provided to the point of contact within Sponsor’s clinical supplies group who is identified to ▇▇▇▇▇ in writing upon the execution of the Agreement and thereafter promptly following any change to such point of contact.